Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1

Psychometric properties of the Itch Numeric Rating Scale in patients with moderate-to-severe plaque psoriasis

(2016) A.B. Kimball et al.   BRITISH JOURNAL OF DERMATOLOGY

Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials

(2015) Christopher E M Griffiths et al.   LANCET

Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial

(2015) Iain B McInnes et al.   LANCET

Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis

(2015) Philip J. Mease et al.   NEW ENGLAND JOURNAL OF MEDICINE

Brief Report: Enrichment of Activated Group 3 Innate Lymphoid Cells in Psoriatic Arthritis Synovial Fluid

(2015) Emmerik F. A. Leijten et al.   Arthritis & Rheumatology

Current Concepts in Psoriatic Arthritis: Pathogenesis and Management

(2014) K Vlam et al.   ACTA DERMATO-VENEREOLOGICA

Brodalumab, an Anti-IL17RA Monoclonal Antibody, in Psoriatic Arthritis

(2014) Philip J. Mease et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immunomodulation in psoriatic arthritis: Focus on cellular and molecular pathways

(2012) Maria Sole Chimenti et al.   AUTOIMMUNITY REVIEWS

Role of IL-17 in Psoriasis and Psoriatic Arthritis

(2012) Siba P. Raychaudhuri   CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY

Anti–Interleukin-17 Monoclonal Antibody Ixekizumab in Chronic Plaque Psoriasis

(2012) Craig Leonardi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Interleukin-17-positive mast cells contribute to synovial inflammation in spondylarthritis

(2011) Troy Noordenbos et al.   ARTHRITIS AND RHEUMATISM

Mast Cells and Neutrophils Release IL-17 through Extracellular Trap Formation in Psoriasis

(2011) A. M. Lin et al.   JOURNAL OF IMMUNOLOGY

Minimally Important Difference of Health Assessment Questionnaire in Psoriatic Arthritis: Relating Thresholds of Improvement in Functional Ability to Patient-rated Importance and Satisfaction

(2011) P. J. MEASE et al.   JOURNAL OF RHEUMATOLOGY

Psoriatic arthritis

(2009) Dafna D. Gladman   Dermatologic Therapy

Circulating Th17, Th22, and Th1 Cells Are Increased in Psoriasis

(2009) Shinji Kagami et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate

(2008) G Wells et al.   ANNALS OF THE RHEUMATIC DISEASES

Increased numbers of circulating polyfunctional Th17 memory cells in patients with seronegative spondylarthritides

(2008) Camilla Jandus et al.   ARTHRITIS AND RHEUMATISM

Measuring clinical enthesitis in psoriatic arthritis: Assessment of existing measures and development of an instrument specific to psoriatic arthritis

(2008) Paul J. Healy et al.   ARTHRITIS AND RHEUMATISM